Strides Pharma Science Limited
STAR.NS

$1.7 B
Marketcap
$18.48
Share price
Country
$-1.01
Change (1 day)
$19.92
Year High
$5.55
Year Low

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

marketcap

P/E ratio for Strides Pharma Science Limited (STAR.NS)

P/E ratio as of 2023: -58.86

According to Strides Pharma Science Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -58.86. At the end of 2022 the company had a P/E ratio of -11.17.

P/E ratio history for Strides Pharma Science Limited from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 -58.86
2022 -11.17
2021 -6.56
2020 28.20
2019 79.28
2018 13.13
2017 8.69
2016 23.02
2015 43.47
2014 11.71
2013 -11.48
2012 10.85
2011 14.97
2010 30.70
2009 18.26
2008 6.93
2007 -47.39
2006 76.86
2005 53.28
2004 40.50